5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence
    Meeting Abstract

    Bajorin, D. F.; Sharma, P.; Sims, R. B.; Sandler, A.; Lerner, S. P.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Fluorodeoxyglucose (FDG) positron emission tomography (PET) as an indicator of disease progression for patients with castration-resistant metastatic prostate cancer (CRMPC)
    Meeting Abstract

    Baklajian, A.; Dennis, E. R.; Buddle, J. R.; Fox, J. J.; Schoder, H.; Morris, M. J.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase II trial of gemcitabine, carboplatin, and bevacizumab (Bev) in patients (pts) with advanced/metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Balar, A. V.; Milowsky, M. I.; Apolo, A. B.; Ostrovnaya, I.; Iasonos, A.; Trout, A.; Regazzi, A. M.; Garcia-Grossman, I. R.; Gallagher, D. J.; Bajorin, D. F.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A noncomparative randomized phase II study of two dose levels of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC): A DOD/PCCTC trial
    Meeting Abstract

    Antonarakis, E. S.; Heath, E. I.; Smith, D. C.; Rathkopf, D. E.; Blackford, A. L.; Danila, D. C.; King, S.; Frost, A.; Carducci, M. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Improved survival outcomes in clinically relevant patient subgroups from COU-AA-301, a phase III study of abiraterone acetate (AA) plus prednisone (P) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel-based chemotherapy
    Meeting Abstract

    Scher, H. I.; Logothetis, C.; Molina, A.; Goodman, O. B.; Sternberg, C. N.; Chi, K. N.; Kheoh, T. S.; Haqq, C. M.; Fizazi, K.; De Bono, J. S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Preliminary results
    Meeting Abstract

    Slovin, S. F.; Kargman, M.; Durso, R.; Curley, T.; Israel, R. J.; Olson, W. C.; Morris, S.; Murphy, D.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Molina, A. M.; Feldman, D. R.; Ginsberg, M. S.; Fischer, P.; Trinos, M. J.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload
    Meeting Abstract

    Morris, M. J.; Farrelly, J. S.; Fox, J. J.; Dennis, E. R.; Schwartz, L. H.; Schoder, H.; Haupt, E. C.; Borwick, L. S.; Larson, S. M.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial
    Meeting Abstract

    Motzer, R. J.; Hutson, T. E.; Olsen, M. R.; Hudes, G. R.; Burke, J. M.; Edenfield, W. J.; Wilding, G.; Martell, B.; Hariharan, S.; Figlin, R. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Motzer, R. J.; Bhargava, P.; Esteves, B.; Al-Adhami, M.; Slichenmyer, W.; Nosov, D.; Eisen, T.; Sternberg, C. N.; Hutson, T. E.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save